tofacitinib / Generic mfg. - LARVOL DELTA

Infections and Therapy Lapses Predominate as Flare Triggers on Oral JAK Inhibitors for Alopecia Areata: A Retrospective Cohort Study (AAD 2026) - " Of 52 records, 39 patients responded to treatment (baricitinib 19, tofacitinib 18, ritlecitinib 2). Flares are common even among responders, most frequently following infectious exposures or treatment interruptions, often related to insurance issues. Proactive counseling, measures to prevent coverage gaps, and a standardized rescue protocol are recommended."

Retrospective data • Alopecia • Immunology • Infectious Disease • Novel Coronavirus Disease

Modulating the JAK–STAT pathway reduces cytotoxic T-lymphocyte activation in the treatment of Stevens–Johnson syndrome and toxic epidermal necrolysis (AAD 2026) - P=N/A | "Our findings establish JAK1/3-STAT1 signaling as a pivotal mediator in the immunopathogenesis of SJS/TEN, underscoring targeted pathway inhibition as a promising therapeutic strategy. Clinical data strongly support tofacitinib's efficacy in reducing disease severity and accelerating skin recovery, advocating further investigation of JAK1/3 inhibitors as viable treatments for severe cutaneous adverse drug reactions."

Steven-Johnson Syndrome • CD8 • GZMB • IFNG • JAK1 • JAK3 • STAT3

Hitting 3 Birds with One Stone: Oral JAK inhibition successfully treats refractory lichen planopilaris, oral lichen planus and vulvar lichen sclerosus (AAD 2026) - "All patients had long-standing refractory LPP, oral lichen planus, and vulvar lichen sclerosus, despite use of corticosteroids, calcineurin inhibitors, hydroxychloroquine, systemic immunomodulators, and topical JAK inhibitors. After starting an oral JAK inhibitor, either baricitinib 4 mg/day or tofacitinib 5 mg twice daily, each showed significant improvement within 6-12 weeks with sustained control thereafter...Therapy was well-tolerated, with no adverse events observed. Discussion This case series provides clinical evidence that oral JAK inhibition can effectively control inflammation in scarring alopecias, such as LPP, while also improving concurrent mucosal disease, particularly in refractory cases."

Alopecia • Dermatology • Dermatopathology • Immunology • Inflammation • Lichen Planus

Treatment of drug reaction with eosinophilia and systemic symptoms with tofacitinib: a pilot study with dynamic cytokines profiles investigation (AAD 2026) - "After clinical improvement, corticosteroids were successfully tapered while maintaining disease control. Our findings suggest that tofacitinib may be a safe and effective alternative therapy for patients with recalcitrant DRESS or limited tolerance to corticosteroids."

Clinical • Eosinophilia • CSF2 • IFNG • IL15 • IL5 • JAK1 • JAK3

Safety of Janus kinase inhibitors for treatment of alopecia areata (AAD 2026) - "Among the remaining 118 patients, 78 (66.1%), 66 (55.9%), 34 (28.8%), 11 (9.3%), and 4 (3.4%) were treated with baricitinib, tofacitinib, ritlecitinib, upadacitinib, and ruxolitinib, respectively. These results show a low incidence of serious AEs, suggesting that JAK inhibitors are well tolerated for the treatment of AA in real-world settings. Further investigations are needed to establish the long-term safety profiles of JAK inhibitors for the treatment of AA."

Clinical • Acne Vulgaris • Alopecia • Cardiovascular • Genito-urinary Cancer • Herpes Simplex • Herpes Zoster • Immunology • Infectious Disease • Pneumonia • Renal Cell Carcinoma • Respiratory Diseases • Solid Tumor • Varicella Zoster

Clinical Characteristics of JAK Inhibitor-Associated Acne: A Retrospective Review (AAD 2026) - " We retrospectively reviewed charts of patients at Mount Sinai Dermatology prescribed oral JAK inhibitors (abrocitinib, upadacitinib, tofacitinib, ritlecitinib, or baricitinib) with a documented diagnosis of acne...The most frequently used acne treatments were topical tretinoin (n=20), clindamycin (n=18), and oral doxycycline (n=18)... As JAK inhibitor prescriptions rise, acne is an increasingly observed dermatologic adverse event. Defining risk profiles and timing may enhance patient counseling, clinical monitoring, and therapeutic decision-making."

Retrospective data • Review • Acne Vulgaris • Immunology

Clinical Utility and Tolerability of Dupilumab and Janus Kinase Inhibitor (JAKi) Combination Therapy in Alopecia Areata Patients (AAD 2026) - "JAKi therapies included tofacitinib, ritlecitinib, and baricitinib. JAKi-dupilumab combination therapy was well tolerated and effective in three AA patients with inadequate JAKi or dupilumab monotherapy response and/or concomitant AD, warranting larger cohort studies."

Clinical • Combination therapy • Allergic Rhinitis • Alopecia • Contact Dermatitis • Dermatitis • Immunology • Infectious Disease • Inflammation • Nephrology • Novel Coronavirus Disease • Ocular Infections • Ophthalmology • Respiratory Diseases

Oral tofacitinib in treatment of chronic actinic dermatitis (AAD 2026) - "Minor adverse effects (headache, dyslipidemia) occurred in 3 patients. Results of this pilot study suggest that tofacitinib is efficacious and well-tolerated, supporting its use as a potential primary treatment in CAD and justifying further clinical trials."

Atopic Dermatitis • Dermatitis • Dermatology • Dyslipidemia • Immunology • Metabolic Disorders

Treatment of Generalized Granuloma Annulare with JAK Inhibitors: A Systematic Review (AAD 2026) - "Agents included tofacitinib (n=28), baricitinib (n=11), upadacitinib (n=10), abrocitinib (n=1), and ruxolitinib (n=1). JAK inhibitors demonstrate consistent efficacy and manageable safety in refractory GGA, supporting their role as a promising targeted therapy. Current evidence is limited to small studies with moderate to high risk of bias. Larger controlled trials are needed to establish long-term efficacy, durability, and optimal dosing."

Review • Dyslipidemia • Herpes Zoster • Infectious Disease • Rare Diseases • Varicella Zoster

Comparative Safety Profiling of Four JAK Inhibitors in Real-World Data: FAERS Disproportionality and Time-to-Event Analysis (AAD 2026) - " FDA Adverse Event Reporting System (FAERS) reports from January 2022 to March 2025 for upadacitinib (n=47,075), abrocitinib (n=2,575), baricitinib (n=3,278), and tofacitinib (n=50,211) were analyzed. Differential AE profiles among JAK inhibitors were observed, with selective JAK1 inhibitors (upadacitinib, abrocitinib) generally exhibiting lower infection, thromboembolic, and malignancy risks compared with baricitinib. Time-to-onset analysis highlights early AE occurrence followed by decline, providing insight for clinical monitoring."

Clinical • Real-world • Real-world evidence • Acne Vulgaris • Cardiovascular • Cataract • Gastroenterology • Gastrointestinal Disorder • Hepatology • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Bowel Disease • Musculoskeletal Diseases • Ophthalmology • Thrombosis • Ulcerative Colitis • Varicella Zoster

A Comparative Study of Intralesional Triamcinolone Acetonide Versus Fractional Carbon-dioxide laser assisted delivery of topical tofacitinib in alopecia areata (AAD 2026) - "However the difference between the two groups was not statistically significant (p=0.061) .Trichoscopic activity resolved in all patients by 12 weeks with minimal side effects in both the groups. Our findings suggest that fractional laser-assisted drug delivery of topical tofacitinib may provide a viable alternative to intralesional triamcinolone in patchy AA."

Aesthetic Medicine • Alopecia • Immunology

Drug Utilisation Study in psoriasis: Real world analysis from India (AAD 2026) - "Apremilast was often used early and across severities. Methotrexate, cyclosporine, and tofacitinib were preferentially used in relapses and higher BSA. Apremilast use was generally stable across common comorbidities, while methotrexate and cyclosporine were preferred in diabetes and renal diseases."

Clinical • Real-world • Real-world evidence • Cardiovascular • Dermatology • Diabetes • Dyslipidemia • Genetic Disorders • Hypertension • Immunology • Metabolic Disorders • Nephrology • Obesity • Plaque Psoriasis • Psoriasis • Renal Disease

The real-world impact of JAK inhibitor treatment on anxiety and depression outcomes and the role of eyebrow and eyelash hair regrowth in alopecia areata: TARGET-DERM (AAD 2026) - "JAKis used included baricitinib (n=21), ritlicitinib (n=10), and tofacitinib (n=6). Most patients showed MID reduction in ClinROs and PROs with JAKis. However, limited PRO responses underscore the need for larger real-world prospective studies evaluating anxiety and depression outcomes with JAKis in AA."

Clinical • Real-world • Real-world evidence • Alopecia • CNS Disorders • Depression • Immunology • Mood Disorders • Psychiatry

Upadacitinib for the Treatment of Refractory Alopecia Areata in Pediatric Patients: A Retrospective Study (AAD 2026) - P3 | "Prior treatments included systemic corticosteroids (n=4, 33.3%), baricitinib (n=7, 58.3%), tofacitinib (n=2, 16.7%), and dupilumab (n=1, 8.3%). This study demonstrated that upadacitinib was effective and well-tolerated in refractory pediatric AA patients unresponsive to prior systemic therapies. In these patients, higher IgE may be associated with earlier response and better efficacy, while a longer current episode duration and eyebrow, eyelash, or nail involvement may be associated with poorer outcomes."

Retrospective data • Alopecia • Immunology • Infectious Disease • Pediatrics • Respiratory Diseases

2% Liposomal Tofacitinib (<200?nm) Overcomes Transcutaneous Delivery Barriers in Eyebrow Alopecia Areata: A Case Report (AAD 2026) - "This case supports the hypothesis that suboptimal results with standard topical tofacitinib stem from poor permeation. The liposomal 2% formulation—featuring nanoparticles <200 nm—enabled effective transcutaneous and follicular delivery, yielding significant and sustained improvement. Liposomal encapsulation of JAK inhibitors warrants further investigation as a targeted topical therapy in limited alopecia areata."

Case report • Clinical • Alopecia • Fibrosis • Immunology • Lichen Planus

Janus Kinase Inhibitors for Alopecia Universalis: A Systematic Review (AAD 2026) - "Tofacitinib was most frequently used (222 cases; mean 10.4 months), followed by deuruxolitinib (53), baricitinib (20), ruxolitinib (19), upadacitinib (8), ritlecitinib (4), abrocitinib (2), and filgotinib (1)... JAKi are promising for AU, with tofacitinib demonstrating the most consistent regrowth. Evidence is limited, and larger trials are needed to confirm efficacy and safety."

Review • Alopecia • CNS Disorders • Hematological Disorders • Herpes Zoster • Immunology • Infectious Disease • Multiple Sclerosis • Varicella Zoster

Navigating Access to JAK Inhibitors for Alopecia Areata: Prescribing Trends, Insurance Denials, and Treatment Delays (AAD 2026) - "Background: Treatment for alopecia areata (AA) has evolved dramatically with FDA approval of three Janus kinase inhibitors (JAKi) for severe AA: baricitinib, ritlecitinib, and deuruxolitinib...Tofacitinib (48.9%), baricitinib (35.6%), and ritlecitinib (13.3%) were the most commonly prescribed agents, largely by dermatologists (94.4%)... Although JAKi prescriptions for AA have risen post-approval, insurance denials and prolonged wait times remain major barriers, even among severe cases. Larger studies are needed to further characterize these disparities and guide strategies to ensure equitable JAKi access."

Reimbursement • US reimbursement • Alopecia • Immunology

Vulvovaginal Lichen Planus Treatment Outcomes: A Systematic Review of Novel and Established Therapies (AAD 2026) - "Among monotherapies, systemic corticosteroids showed highest complete resolution (CR) rates at 88.9%, followed by biologics with tildrakizumab achieving 88% CR, and JAK inhibitors with tofacitinib showing 75% CR. Notably, intravaginal hydrocortisone suppositories achieved 54.6% CR compared to only 14.8% with topical clobetasol propionate, demonstrating superior efficacy of mucosal delivery methods...Recurrence rates varied significantly: 84% for topical corticosteroids alone, 11.9% for methotrexate, and only 3.2% for tildrakizumab, suggesting potential disease-modifying effects of certain biologics...Our findings suggest that intravaginal delivery methods outperform topical application, newer targeted therapies show promise even in treatment-refractory cases, and combination approaches are frequently necessary for adequate disease control. The superior efficacy of JAK inhibitors and biologics, combined with lower recurrence rates, offers new hope for patients with..."

Clinical • Review • Dermatology • Dermatopathology • Lichen Planus

Janus kinase inhibitors' effect on patch testing: a systematic review (AAD 2026) - "Upadacitinib was the most documented JAKi (61.1%) followed by abrocitinib (27.8%), tofacitinib (5.6%) and baricitinib (5.6%). Of this cohort, 71.9% converted to entirely negative patch test results during JAKi treatment, while the remaining 28.1% demonstrated a reduction in number or grade of positive reactions compared with pre-treatment. This review sheds light on the effects of JAKi use on patch testing results with initial findings indicating potentially diminished readings with concurrent JAKi use."

Review • Alopecia • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Immunology • Infectious Disease • Psoriasis

Long-Term Efficacy and Safety of Upadacitinib in Refractory Lichen Planopilaris: The first 30-Month Case Report of extended follow-up (AAD 2026) - "MATERIALS AND We report a case of a 57-year-old female patient with an eleven-year history of refractory LPP, unresponsive to prior treatments including topical and systemic corticosteroids, calcineurin inhibitors, and cyclosporine...Reports on JAKis including tofacitinib, baricitinib, and upadacitinib show benefit in small cohorts with only 9, 12 and 5 patients respectively and relatively short follow-ups... At five months, LPPAI decreased to 1, accompanied by 15% hair regrowth. Continued therapy reaching 30 months resulted in further improvement (LPPAI: 0, hair regrowth: 30%) without adverse effects. Management of LPP remains challenging."

Case report • Clinical • Alopecia • Fibrosis • Immunology • Lichen Planus • Myelofibrosis • JAK1

Genomic landscape of IDH-wild-type glioblastoma in a patient treated with TNF-alpha inhibitor: Implications for risk stratification and therapeutic decision-making (AACR 2026) - "We investigated the genomic profile of a GBM that developed after sequential methotrexate, sulfasalazine, adalimumab, and tofacitinib therapy to explore possible mechanistic links between immunomodulation and tumor evolution.Tumor tissue underwent immunohistochemistry, targeted next-generation sequencing, and copy-number analysis at two independent clinical laboratories. This analysis identifies both canonical and atypical genomic alterations in a GBM arising after prolonged TNF-α-targeted therapy. The absence of a TERT promoter mutation and the presence of an unusual ATRX variant suggest a nonstandard evolutionary trajectory. Although causality cannot be established, the temporal association with TNF-α inhibitor exposure, combined with pathway overlap between TNF-α biology, PTEN/TP53 signaling, and immune regulation, warrants further investigation."

Clinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • ATRX • CDKN2A • CDKN2B • GFAP • KDM6A • PDPK1 • PTEN • TERT

In vitro and in vivo screening platform for discovery of JAK2 inhibitors (AACR 2026) - "We established integrated in vivo and in vitro screening platforms for the discovery and evaluation JAK2 inhibitors. This model provides a valuable tool for optimizing treatment regimens against JAK2-driven pathologies."

Preclinical • Essential Thrombocythemia • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • STAT5

Afatinib exerts an inhibitory effect on T cell-mediated cytotoxicity (AACR 2026) - "In this screening, immunosuppressive agents such as JAK inhibitors (ruxolitinib and tofacitinib) and src inhibitor dasatinib markedly suppressed T cell-mediated killing as expected. Collectively, these findings identify afatinib as a negative regulator of T cell effector function and raise the possibility that EGFR-TKI-induced immunosuppression in T cells may contribute to the limited clinical efficacy of EGFR-TKI plus ICI combinations observed in EGFR-mutant NSCLC. Our screen platform provides a useful framework for predicting drug-ICI interactions and guiding rational combination strategies."

IO biomarker • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • IFNG • WT1

Acquired Perforating Dermatoses Associated With Biologics and Janus Kinase Inhibitor Therapy: A Systematic Review. (PubMed, J Cutan Med Surg) - No abstract available

Journal • Dermatology

Bioluminescent intestinal reporter organoids as in vitro tools to monitor inflammatory effects of compounds (AACR 2026) - "Importantly, treatment with established anti-inflammatory agents, such as Tofacitinib, led to a reduction in elevated reporter activity and downstream cytokine levels. In conclusion, the bioluminescent intestinal NF-kB reporter organoids developed through our optimized protocol represent a high-throughput platform for effectively monitoring the inflammatory effects of potential drug candidates."

Preclinical • Oncology • CXCL8 • IL1B • TNFA